Literature DB >> 21893423

A multicenter retrospective study of childhood brucellosis in Chicago, Illinois from 1986 to 2008.

Latania K Logan1, Norman M Jacobs, James B McAuley, Robert A Weinstein, Evan J Anderson.   

Abstract

OBJECTIVES: To determine risk factors in children for the acquisition of Brucella, clinical presentation, treatment, and disease outcomes.
METHODS: A retrospective multicenter chart review was undertaken of children identified with brucellosis from 1986 to 2008 at three tertiary care centers in Chicago, Illinois, USA. The charts were reviewed for data regarding risk factors for acquisition, clinical presentation, and outcomes.
RESULTS: Twenty-one charts were available for review. The median age was 6.5 years (range 2-14 years); 62% were female. Ethnic background was 67% Hispanic and 24% Arabic. Risk factors included travel to an endemic area (86%), particularly Mexico, and consumption of unpasteurized milk products (76%). Common findings included fever (95%), bacteremia (86%), elevated liver transaminases (80%), constitutional symptoms (76%), splenomegaly (60%), and hepatomegaly (55%). Relapse occurred in three of six subjects started on single drug treatment, but in only one of 15 subjects who started on two or more drugs (p=0.053). No relapses occurred in children whose initial therapy included rifampin or those administered three-drug regimens.
CONCLUSIONS: Brucella is an infrequent pathogen but should be considered in children with compatible epidemiologic and clinical characteristics. Blood cultures should be obtained, and initial therapy with two or more drugs may decrease the risk of relapse.
Copyright © 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21893423     DOI: 10.1016/j.ijid.2011.08.002

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  8 in total

1.  Analysis of Brucellosis Cases Between 2010 and 2020 in Guangdong Province, China.

Authors:  Xiaoxiao Wang; Yunhu Zhao; Suling Liu; Bing Gu
Journal:  Am J Trop Med Hyg       Date:  2022-04-11       Impact factor: 3.707

2.  Brucellosis Outbreak in Children and Adults in Two Areas in Israel.

Authors:  Orli Megged; Bibiana Chazan; Atef Ganem; Abeer Ayoub; Anna Yanovskay; Waheeb Sakran; Dan Miron; Ahuva Dror-Cohen; Yoram Kennes; Svetlana Berdenstein; Daniel Glikman
Journal:  Am J Trop Med Hyg       Date:  2016-04-25       Impact factor: 2.345

3.  Skeletal complications of brucellosis: A study of 464 cases in Babol, Iran.

Authors:  Soheil Ebrahimpour; Masomeh Bayani; Zahra Moulana; Mohammad Reza Hasanjani Roushan
Journal:  Caspian J Intern Med       Date:  2017

4.  Clinical manifestations, laboratory findings, and therapeutic regimen in hospitalized children with brucellosis in an Iranian Referral Children Medical Centre.

Authors:  Fatemeh Fanni; Leila Shahbaznejad; Babak Pourakbari; Shima Mahmoudi; Setareh Mamishi
Journal:  J Health Popul Nutr       Date:  2013-06       Impact factor: 2.000

5.  Targeted Mutation of Nuclear Bone Morphogenetic Protein 2 Impairs Secondary Immune Response in a Mouse Model.

Authors:  Daniel S Olsen; Wesley A Goar; Brandt A Nichols; K Tyson Bailey; S Loyd Christensen; Kayla R Merriam; Paul R Reynolds; Eric Wilson; K Scott Weber; Laura C Bridgewater
Journal:  Biomed Res Int       Date:  2015-08-23       Impact factor: 3.411

6.  Prevalence of Asymptomatic Brucellosis in Children 7 to 12 Years Old.

Authors:  Mohammad Aghaali; Siamak Mohebi; Hosein Heydari
Journal:  Interdiscip Perspect Infect Dis       Date:  2015-10-20

Review 7.  Pediatric brucellosis. An update review for the new millennium.

Authors:  Elham E Bukhari
Journal:  Saudi Med J       Date:  2018-04       Impact factor: 1.484

8.  An Outbreak of Brucellosis: An Adult and Pediatric Case Series.

Authors:  Linda Hassouneh; Syeda Quadri; Patricia Pichilingue-Reto; Sujittra Chaisavaneeyakorn; James B Cutrell; Dawn M Wetzel; Ank E Nijhawan
Journal:  Open Forum Infect Dis       Date:  2019-08-30       Impact factor: 3.835

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.